INTRODUCTION
Multiple myeloma (MM) is a clonal malignancy of bone marrow plasma cells that develops as a consequence of a multistep transformation process [ 1 - 3 ]. Several genetic lesions associated to the activation of signal transduction pathways, which stimulate MM cell survival and proliferation, have been elucidated in the past decade [ 1 - 7 ]. Presently, there is growing evidence that epigenetic events play a major role in MM pathogenesis [ 8 , 9 ]. Changes in DNA methylation are key epigenetic features known to regulate gene expression. In mammalians, DNA methylation is characterized by an enzymatic addition of a methyl group at the carbon 5 position of cytosine in the context of the sequence 5' cytosine-guanosine (CpG) through DNA methyltransferase (DNMTs) activity[ 9 ]. CpG dinucleotides are clustered in regions, named CpG-islands, present in almost 60% of all gene promoters [ 10 ]. Once hyper-methylated, CpG-islands mediate gene-transcriptional silencing [ 11 ]. DNMT isoforms, including DNMT1, DNMT3A and DNMT3B, have distinct roles in genomic methylation[ 12 ]: DNMT3A and DNMT3B are responsible for de novo DNA methylation, whereas DNMT1 accounts for replicating the DNA methylation pattern in genomic DNA [ 13 ]. A number of studies suggest that DNMT genes are frequently overexpressed in human cancer and in the cell transformation process [ 14 - 17 ], though mutations of DNMT genes might also occur [ 18 ]. DNMTs overexpression is produced by different mechanisms, including aberrant cell cycle control, increased mRNA and protein stability, and E2-F-mediated DNMTs promoter activation [ 19 , 20 ]. Most importantly, silencing of tumor suppressor genes by aberrant DNA hyper-methylation has been reported in hematologic malignancies, including acute myeloid leukemia [ 21 ] and multiple myeloma [ 8 , 22 ].
Recent evidence supports a role for microRNAs (miRNAs) as relevant players in aberrant mechanisms of DNA hyper-methylation [ 23 , 24 ]. MiRNAs are an evolutionarily conserved class of small non-coding RNAs (20-24 nucleotides) that regulate gene expression via complete or partial matching to target genes at the 3' untranslated region (UTR), causing suppression of protein translation or messenger RNA (mRNA) degradation [ 25 ]. To date, no evidence of miRNAs involvement in antagonizing aberrant methylation in MM has been reported. Moreover, although their involvement in the pathogenesis of MM has been underlined by several observations, only few miRNAs have been evaluated as therapeutic agents in the treatment of this disease [ 26 , 27 ].
In the present study, we evaluated whether miR-29b could inhibit de novo DNMTs expression. Moreover, synthetic miR-29b oligonucleotides formulated with a novel Neutral Lipid Emulsion (NLE) [ 28 ] delivery system were used to evaluate the effect of miR-29b in different and clinically relevant murine xenograft models of human MM, including the most innovative SCID- synth-hu system [ 29 ], which recapitulates the growth of human MM cells within the human bone marrow microenvironment (huBMM)[ 30 ].
RESULTS
Expression of DNMT3A and DNMT3B in MM primary samples and cell lines
We first evaluated the expression of DNMT3A, DNMT3B and DNMT1 mRNAs on a dataset of high-density cDNA-microarrays of primary CD138 + cells from intramedullary MM (n=55) or PCL (n=5) patients and from normal healthy donors (PCs, n=4). As compared to normal CD138 + cells, PCs from MM and PCL patients showed higher expression of DNMT3A (Fig. 1A ), and, at a lesser extent, of DNMT3B mRNAs (Fig. 1B ), suggesting a potential role of de novo DNMTs in malignant transformation; conversely, DNMT1 levels were lower in cancer cells compared to normal PCs ( Supplemental Fig. 1 ). To determine whether the bone marrow microenvironment (BMM), which triggers the proliferation and supports the survival of MM cells, could affect de novo DNMTs expression, KMS12 and NCI-H929 MM cell lines were cultured for 12 or 24 hours adherent to bone marrow stromal cells (BMSCs) and DNMT3A and DNMT3B levels were then analyzed by q-RT-PCR (Fig. 1C ). Interestingly, adhesion of MM cells to BMSCs induced up-regulation of DNMT3A and DNMT3B mRNA levels in both MM cell lines, suggesting that the BM milieu might influence DNA methylation of MM cells.
miR-29b targets de novo DNMTs in MM cells
In silico search for target prediction [ 31 , 32 ] indicates that both DNMT3A and DNMT3B are bona fide targets of miR-29b. To validate this interaction in MM cells, INA-6 cells were co-transfected with synthetic miR-29b or scrambled oligonucleotides (NC), together with an expression vector carrying the 3'UTR of DNMT3A or DNMT3B mRNA cloned downstream to the luciferase reporter gene. Figure 2A shows miR-29b levels after transfection. A significantly lower luciferase activity in INA-6 cells transfected with miR-29b mimics as compared to control was detected (Fig. 2B ). Consistently, miR-29b transfection reduced DNMT3A and DNMT3B mRNA (Fig. 2C ) and protein levels (Fig. 2D , left panel), as assessed by q-RT-PCR and western blotting analysis. On the basis of these findings we investigated whether miR-29b inhibition could up-regulate de novo DNMTs expression. SKMM1 cells were stably transduced with a lentiviral vector carrying the antagomiR-29b; miR-29b levels after transduction are reported in Supplemental Fig. 2 . Of note, miR-29b inhibition indeed led to up-regulation of both DNMT3A and DNMT3B protein levels, as assessed by western blotting analysis (Fig. 2D , right panel). It was possible to conclude that miR-29b is a direct regulator of DNMT3A and DNMT3B expression in MM cells. These findings also suggested that miR-29b could induce epigenetic modifications in cancer cells. To address this issue, we transfected either NCI-H929 or U266 MM cells with miR-29b synthetic mimics or scrambled oligonucleotides and the global methylation levels were measured by a well established luminometric method [ 33 ]. MiR-29b levels after transfection are reported in supplemental Fig. 3 . As shown in Fig. 2E , miR-29b transfection resulted in a robust reduction of the global methylation levels of MM cell lines, thus supporting its role in the epigenetic control of MM cells.
Inverse correlation between miR-29b and DNMT3B in MM cell lines
To assess the relevance of the interaction between miR-29b and de novo DNMTs, we analyzed the correlation between miR-29b and DNMT3A or DNMT3B mRNA levels in a panel of 17 MM cell lines. Raw microarray expression levels for DNMT3A, DNMT3B and miR-29b are reported in Supplemental Fig. 4 . Notably, such integrated analysis highlighted an inverse correlation between miR-29b and DNMT3B expression levels (p=0,0012), whereas no correlation between miR-29b and DNMT3A could be demonstrated (Fig. 3 ).
Synthetic miR-29b mimics impair cell cycle progression and potentiate 5-azacitidine effects
We subsequently studied in vitro effects produced by targeting de novo DNMTs in MM cells. In details, NCI-H929 MM cells were stably transduced with two different shRNAs against DNMT3A or DNMT3B or with a scrambled control. After lentiviral transduction, cells were selected with puromycin and levels of DNMT3A and DNMT3B mRNAs were analyzed by q-RT-PCR ( Supplemental Fig. 5 ). Interestingly, de novo DNMTs silencing significantly altered cell cycle of MM cells, as revealed by both the strong decrease in S-phase and the relevant increase in hypodiploid cells, indicative of apoptosis, in cells silenced for DNMT3A and DNMT3B compared to scrambled-transduced cells (Fig. 4A ). These findings indicate that de novo DNMTs represent promising targets for therapeutic intervention in MM. Then, we studied the effects induced by synthetic miR-29b mimics, alone or in combination with the demethylating agent 5-azacitidine, on cell growth and cell cycle regulation of MM cells. In vitro transfection of synthetic miR-29b mimics decreased cell growth in a time-dependent manner and potentiated 5-azacitidine anti-proliferative effects at 72 hours (percentage of growth inhibition at 72 hours were 45%, 35% and 65% for miR-29b, 5-azacitidine and combination treatment respectively; Fig. 4B ). Cell cycle analysis revealed that miR-29b induced apoptosis, as assessed by the increase of hypodiploid cell percentage, to an extent similar to that caused by 5-azacitidine; the combined treatment produced, at 72 hours, an increase of apoptosis and decrease in S-phase as compared to miR-29b or 5-azacitidine treatment alone (Fig. 4C ). These results suggest that the potentiation on cell growth inhibition is likely due to the perturbation of cell cycle distribution and to the increase of apoptosis occurrence.
Synthetic miR-29b mimics exert anti-MM activity in vivo
The effect of miR-29b on MM cell growth in vivo was evaluated in 2 different experimental systems. In a first model, we explored the in vivo anti-tumor potential of miR-29b on MM xenografts in SCID mice by intratumor delivery of synthetic miR-29b-mimics. SKMM1 MM cells were injected in a cohort of 15 mice and when tumors became palpable, mice were randomized into 3 groups and treated intratumorally with synthetic miR-29b mimics, miR-NC or vehicle alone. To achieve an efficient delivery of miR-29b or miR-NC, we formulated synthetic miR-29b-mimics with NLE particles [ 28 ], a novel in vivo delivery system for oligonucleotides. As shown in Fig. 5A , repeated intratumor injection of NLE-formulated synthetic miR-29b (1mg/Kg; 5 injections, 3 days apart), significantly inhibited growth of MM xenografts. Our findings demonstrate that the delivery of synthetic miR-29b mimics exerts anti-MM activity in vivo . Importantly, the growth-inhibitory effect well correlated with miR-29b accumulation in tumor tissues (Fig. 5B ), as assessed by q-RT-PCR in retrieved xenografts. We next explored the potential anti-tumor activity of systemic delivered formulated miR-29b mimics. Xenografted mice were randomized to receive synthetic miR-29b or miR-NC (1mg/kg per mouse), each formulated with NLE particles, via tail vein. Following 3 injections (3 days apart), a significant anti-tumor effect of NLE-formulated miR-29b was detected (Fig. 5C ). We observed significant tumor growth inhibition (p<0.05) in mice treated with miR-29b mimics, together with 2-fold increase of miR-29b levels (Fig. 5D ) and down-regulation of both DNMT3A and DNMT3B mRNA levels (Fig. 5E ) as assessed by qRT-PCR analysis of the excised tumors. Notably, miRNAs administration did not produce any significant behavioral changes or weight loss in treated animals. No pathologic features were detected by histological analysis of tissues, including liver, lung, kidney and bone marrow of treated mice, clearly indicating absence of acute toxicity (not shown).
Finally, we evaluated the effect of miR-29b mimics in SCID- synth-hu mice [ 29 ]. In this model, MM cells adhere to BMSCs within a 3D biopolymeric scaffold into immunocompromised mice, recapitulating MM growth within an adult BM MM-derived milieu . We used the bone marrow-dependent INA-6 cells to evaluate if miR-29b overcome the growth-supportive effect induced by the huBMM. Histological and immunohistochemical analysis of retrieved 3D biopolymeric scaffolds after treatment with synthetic miR-29b showed indeed increased expression of cleaved caspase-3 and reduced Ki-67 (Fig. 6 ).
All together, these findings indicate that miR-29b exerts anti-tumor activity in vivo , providing a strong rationale for clinical development of synthetic miR-29b mimics in MM.
DISCUSSION
A number of complex and interdependent epigenetic modifications are involved in cancer development and progression [ 34 ]. Alteration of DNA methylation has been reported in hematologic malignancies like acute myeloid leukemia [ 35 ] as well as in solid tumors [ 36 , 37 ], which often display increased levels of DNMTs compared to their normal counterpart, suggesting that DNMTs overexpression contributes to tumorigenesis [ 35 ]. In the present work, we show that de novo DNMTs mRNA levels are increased in MM and PCL primary samples, indicating a potential role of altered DNA methylation in myelomagenesis. Most importantly, we provide the first evidence that the huBMM increases de novo DNMTs expression and therefore could interfere with epigenetic control of MM cell growth and survival.
MiRNAs recently emerged as key players in MM pathophysiology [ 26 ]. To investigate the relationship between the miRNA network and de novo DNMTs in MM, we studied the regulatory role of miR-29b on DNMTs expression and global DNA methylation in MM cells. Indeed, bioinformatic analysis revealed that DNMT3A and DNMT3B are miR-29b targets, according with previous studies which reported the ability of members of the miR-29-family to target DNMTs in solid tumors and AML [ 24 , 38 ]. Interestingly, the integrated analysis of miRNA/mRNA profiling revealed an inverse correlation between miR-29b and DNMT3B in a panel of 17 MM cell lines, underscoring a key role of miR-29b on DNMT3B regulation.
We here demonstrate that synthetic miR-29b mimics specifically bind the 3'UTR of DNMT3A and DNMT3B, resulting in downregulation of both DNMTs at mRNA and protein level; conversely, miR-29b inhibition by antagomiRs led to increased DNMTs expression levels. Notably, miR-29b mimics resulted in epigenetic changes, as demonstrated by an approximately 2-fold decrease in global DNA methylation in MM cells. At our knowlewdge, this is the first evidence that a microRNA is able to affect the methylation profile in MM cells. Our results are in line with previous reports showing that enforced expression of miR-29b reduces global DNA methylation in AML and NSCLC cells, restoring the expression of methylation-silenced tumor suppressor genes (TSGs). A variety of TSGs, i.e. VHL, XAF1, IRF8, SOCS1, SOCS3 and CDKN2A, have been found to be promoter-hypermethylated in MM cells. TSGs hypermethylation confers an adverse outcome in MM patients [ 39 - 43 ]. A follow-up study will shade light on TSGs under miR-29b regulation by DNA-methylation control.
In the present report, we also provide insights into biological effects triggered by synthetic miR-29b mimics in vitro and in vivo . Tumor suppressive role of miR-29b has been previously reported in solid tumors [ 24 , 44 ] and haematologic malignancies [ 45 ], although it remains controversial in CLL [ 46 ]. In our experimental model, in vitro transfection of synthetic miR-29b mimics in MM cells promoted apoptosis and cell cycle perturbations, and similar effects were observed when DNMT3A and DNMT3B were silenced by shRNAs, just confirming the thought that these enzymes are valuable targets for anti-tumor treatment. Moreover, synthetic miR-29b mimics potentiated the growth-inhibitory effects of the DNMT-inhibitor 5-azacitidine [ 47 ], suggesting new strategies based upon DNA-demethylating agents/miRNAs combination in the treatment of MM. The in vivo anti-tumor potential of miR-29b was demonstrated in different clinically relevant murine models of human MM. Our experimental platform was based on xenografts of MM cells that were exposed to synthetic miR-29b mimics delivered via NLE, a novel lipid-based delivery system. In order to additionally support the clinical translation of our experimental approach, we also studied the in vivo activity of miR-29b mimics using the novel SCID- synth-hu model of human MM [ 29 ]. In this biosynthetic and orthotopic model, tumor cells grow within a bone-like 3D biopolymeric scaffold previously engrafted with human BMSCs, recapitulating a human BM milieu in SCID mice. In this model, delivery of systemic miR-29b mimics induced significant anti-tumor effects, as demonstrated by immunohistochemical analysis of retrieved scaffolds, demonstrating the ability of miR-29b to overcome the protective role of BMSCs.
In conclusion, we provide evidence that miR-29b controls the methylation profile of MM cells suggesting that miR-29b down-regulation may play a relevant role in MM pathophysiology by reducing TSGs expression. Moreover, miR-29b mimics appear a promising agent in the treatment of MM, alone or in combination with demethylating drugs.
MATERIALS AND METHODS
MM Patient samples and cell lines
Bone marrow mononuclear cells (BMMNCs) and primary MM cells from 55 newly diagnosed untreated MM and 8 plasma cell leukemia (PCL) patients following informed consent and University Magna Graecia IRB approval, were isolated by Ficoll-Hypaque density gradient sedimentation and obtained during standard diagnostic procedures after informed consent in accordance with Institutional guidelines. MM patient cells were separated from BM samples by antibody-mediated positive selection using anti-CD138 magnetic activated cell separation microbeads (Miltenyi Biotech, Gladbach, Germany). Plasma cells (PCs) from tonsils of five healthy donors were also purified and included in the study. The purity of the positively selected PCs was assessed by means of morphology and flow cytometry and was > 90% in all cases. The 55 MM employed for microarray analysis were selected on the basis of the representativeness of their molecular characteristics in order to minimize patient selection biases. MM cell lines (SKMM1, NCI-H929, INA-6, CMA-03, CMA-0306, DELTA47, KMS11, KMS12BM, KMS18, KMS20, KMS26, KMS34, LP1, MM.1.144, MM1S, OPM2, U266 and UTMC2) were cultured in RPMI 1640 (Gibco, Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum (Lonza Group Ltd., Switzerland). The IL-6 dependent MM cell Line INA-6 (kindly provided from Dr Renate Burger, University of Erlangen-Nuernberg, Erlangen, Germany) was cultured in the presence of rhIL-6 (R&D Systems, Minneapolis, MN) as described [ 48 , 49 ]. BMSCs were established as described [ 50 ]. 5-Azacitidine was purchased from Sigma Aldrich and dissolved in RPMI medium as indicated by the manufacturer.
Gene Expression Profiling
Gene expression profiles were analyzed on the GeneChip ® Human Gene 1.0 ST chip platform (Affymetrix Inc., Santa Clara, CA). The raw intensity expression values were processed by Robust Multi-array Average (RMA) complete procedure (Irizarry Biostatistics 2003) with the re-mapped Chip Definition Files (CDF) from BrainArray libraries version 15.0.0 available at http://brainarray.mbni.med.umich.edu/Brainarray/Database/Custom CDF/ 15.0.0/entrezg.asp .
miRNA profiling
MiRNA expression profiling was carried out using Total RNA and Affymetrix GeneChip miRNA 1.0 according to manufacturer's recommended protocol. Expression values were extracted with Affymetrix miRNA QC tool (RMA normalized and log2-transformed).
In vitro transfection of MM cells with synthetic miR-29b
Synthetic pre-miRNAs were purchased from Ambion (Applied Biosystems). 1×10 6 cells were electroporated with scrambled (miR-NC) or synthetic pre-miR-29b (miR-29b) at a final concentration of 100nM, using Neon® Transfection System (Invitrogen), with 1050 V, 30 ms, 1 pulse. Cell transfection efficiency was evaluated by flow cytometric analysis of FAM TM -dye-labeled synthetic miRNA inhibitor (Invitrogen) transfection.
Virus Generation and Infection of MM cells
The human DNMT3A and DNMT3B mission shRNA set (Sigma) and the mission nontarget control transduction virus (SHC002V; Sigma) were used to generate lentiviral particles in HEK 293T packaging cells as previously described [ 51 ]; two rounds of transduction of MM cells in the presence of 8 μg/ml of polybrene (Sigma) were performed. Two days after transduction, transduced cells were selected with 1 μg/ml Puromycin (Sigma). Transduced cells underwent two rounds of infection (8 hours each round) and were selected in medium containing 1 μg/ml puromycin. To obtain MM cells stably expressing antagomiR-29b, we used the lentiviral vector miRZip29b anti-miR-29b construct (System Biosciences); lentiviral particles production and transduction were performed according to the above indicated protocols. Selection was performed in medium containing 1 μg/ml puromycin.
Quantitative real-time amplification of miRNAs and mRNAs
Total RNA from MM cells was prepared with the TRI z ol® Reagent (Invitrogen) according to manufacturer´s instructions. The single-tube TaqMan miRNA assays (Applied Biosystems, Assay id 000413) was used to detect and quantify mature miR-29b according to the manufacturer's instructions, by the use of iQ5 multicolor detection system (Bio-Rad). miR-29b expression was normalized on RNU44 (Applied Biosystems, Assay Id 001094). For mRNA dosage studies, oligo-dT-primed cDNA was obtained using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and then used as template to quantify DNMT3A (Hs01027166_m1) and DNMT3B (Hs00171876_m1) levels by TaqMan assay (Applied Biosystems); normalization was performed with GAPDH (Hs03929097_g1). Comparative real-time polymerase chain-reaction (RT-PCR) was performed in triplicate, including no-template controls. Relative expression was calculated using the comparative cross threshold (Ct) method [ 52 ].
Luciferase reporter experiments
The 3' UTRs of DNMT3a and DNMT3B were cloned in pEZX-MT01 vector and purchased from Genecopoeia. MM cells were electroporated as above described using 10μg of the firefly luciferase report; for each plate, 100 nM of the synthetic miR-29b or miR-NC were used. Firefly and Renilla luciferase activities were measured consecutively using the dual-luciferase assay kit (Promega) 24 hours after transfection.
DNA extraction and measurement of global DNA methylation levels
DNA was extracted by a commercial kit (Invitrogen). The global DNA methylation levels of MM cell lines transfected with syntehtic miR-29b mimics or scrambled oligonucleotides (NC) were estimated according to our previous report [ 33 ]. The data were expressed as Global DNA Methylation Index (GDMi) by dividing the mean net luminescence values for the HpaII enzyme to the mean net luminescence values for the MspI enzyme. Thus, the GDMi values inversely correlate to the global DNA methylation levels.
Cell proliferation and cell cycle analysis
For cell proliferation analysis, MM cells were plated in 6 well plates, electroporated with miR-29b or miR-NC and then harvested, plated at 1,5-2,0×10 5 /mL, and counted at 24-hour intervals using a Trypan Blue-exclusion assay. Each sample was run at least in triplicate. Cell cycle analysis was performed as previously reported [ 53 ].
Western blotting
SDS-PAGE and Western Blotting (WB) were performed according to standard protocols[ 35 ]. Briefly cells were lysed in lysis buffer containing 15mM Tris/HCl pH 7.5, 120mM NaCl, 25mM KCl, 1mM EDTA, 0.5% Triton 100, Halt Protease Inhibitor Single-Use cocktail (100X, Thermo Scientific). Whole cells lysates (50μg per lane) were separated using 4-12% Novex Bis-Tris SDS-acrylamide gels (Invitrogen), electro-transferred on Nitrocellulose membranes (Bio-Rad), and immunoblotted with the rabbit anti-DNMT3A, anti-DNMT3B or anti-GAPDH (Santa Cruz Biotechnology) antbodies.
Animals and in vivo models of human MM
Male CB-17 severe combined immunodeficient (SCID) mice (6- to 8-weeks old; Harlan Laboratories, Inc., Indianapolis) were housed and monitored in our Animal Research Facility. All experimental procedures and protocols had been approved by our Institutional Ethical Committee and conducted according to protocols approved by the National Directorate of Veterinary Services (Italy). Procedures were performed as previously described [ 53 ]. Briefly, mice were sacrified when their tumors reached 2 cm in diameter or in the event of paralysis or major compromise in their quality of life, to prevent unnecessary suffering, as previously described [ 54 ]. For our study, we used 2 different models of human MM, including i) SCID mice bearing subcutaneous (sc) MM xenografts [ 55 ]; and ii) SCID mice implanted with a 3D polymeric scaffold previously reconstituted with human bone marrow stromal cells and then injected with INA6 human MM cells (SCID-synth-hu)[ 30 ].
i) Xenograft of MM cell lines in SCID mice
For this model, mice were sc inoculated in the interscapular area with 5 × 10 6 MM cells cells in 100 μL RPMI-1640 medium. Treatment was initiated after the detection of palpable tumors, approximately 3 weeks following injection of MM cells. Tumor sizes were measured weekly in 2 dimensions using a caliper, and volume was calculated using the formula: V = 0.5 × a × b 2 , where a and b are the long and short diameter of the tumor, respectively, until the tumor was palpable. Mice were randomized in 3 groups and treated with synthetic miR-29b mimics or miR-NC or vehicle alone or PBS. Each dose contained 20 μg synthetic oligo which equals 1mg/kg per mouse with an average weight of 20g. Administration of miRNA-mimics was performed by the use of the novel formulation of neutral lipid emulsion (NLE) (MaxSuppressor in vivo RNA Lancer II, BIOO Scientific, Austin, TX) according to the manifacturer's instructions. Treatments were first performed intratumorally (i.t.) every three days for a total of four injections. In a subsequent series of experiments, treatments were performed systemically via tail vein by using the same formulation and dosage/schedule of the intratumoral injections. Tumors were then collected and placed in either 10% formalin for histology or in RNA later ® for RNA isolation.
ii) SCID-synth-hu model
The SCID- synth-hu model was reproduced by implantation into a SCID mouse of a three-dimensional (3D) bone-like poly-Σ-caprolactone polymeric scaffold (PCLS)[ 29 ]. PCLS cylinders (7mm in length and 3mm in diameter at scanning electron microscope SEM), demonstrated interconnected large (100–300 mm) and small pores (1–10 mm) resembling the micro-architecture of a normal human adult bone, as described. Dynamic seeding of BMSCs into PCLSs was performed as previously reported. Briefly, using a suspension of 8×10 5 cells in 500 μl of growth medium, a 22-gauge needle on a 2.5 ml syringe was threaded into two ending faces of the cylindrical scaffold. A medium flow rate of 500 μl/min and three drawing cycles were carried out on both scaffold ends. Before implantation, PCLSs were incubated in complete medium at 37°C in 5% CO2 for 24 h to allow cell adhesion on 3D surfaces. Then, the PCLS was surgically implanted sc into a SCID mouse flank. Chloralium hydrate anesthesia (400 mg/kg, 0,15 ml) was used during all surgical procedures. Three weeks thereafter, 8×10 5 bone marrow-dependent INA-6 cells were injected in vivo into previously implanted PCLSs coated ex vivo with human derived BMSCs. Approximately one month later, when sIL6R became detectable in mice sera, NLE-miR-29b or -NC were injected directly into the scaffold (total of 7 injections, 2 days apart). In vivo effects induced by miR-29b were evaluated by immunohistochemistry on retrieved scaffolds at the end of treatments.
Histology and immunohistochemistry
Retrieved tumors from animals were immediately fixed by immersion in 4% buffered formaldehyde for 24 h at 4 °C, washed, dehydrated and embedded in paraffin. For the light microscopy analysis, sections were cut (4 μm), mounted on poly-lysine slides, and stained with H&E. For immunohistochemistry staining, 2μm thick sections were in a Bond Max Automated Immunohistochemistry according to the following protocol. Tissues were deparaffinized and pre-treated with the Epitope Retrieval Solution 2 (EDTA-buffer pH8.8) at 98°C for 20 min. After washing steps, peroxidase blocking was carried out for 10 min using the Bond Polymer Refine. Tissues were again washed and then incubated with the primary antibody directed against ki67 (Dako, clone: MIB-1; 1:150), capase-3 (NOVOCASTRA, clone: JHM62; 1:500). Subsequently, tissues were incubated with polymer for 10 min and developed with DAB-Chromogen for 10 min. Slides were counterstained with hematoxylin.
Statistical analysis
Student's t test, two-tailed and Log rank test were used to calculate all reported P values using GraphPad software ( www.graphpad.com ). Graphs were obtained using SigmaPlot version 11.0.
Supplementary Figures
This work has been supported by funds of Italian Association for Cancer Research (AIRC), PI: PT. “Special Program Molecular Clinical Oncology - 5 per mille” n. 9980, 2010/15.
The authors declare no competing financial interests.
REFERENCE
1 Chng WJ Glebov O Bergsagel PL Kuehl WM Genetic events in the pathogenesis of multiple myeloma Best Pract Res Clin Haematol 2007 20 4 571 596 18070707 10.1016/j.beha.2007.08.004 PMC2198931
2 Morgan GJ Walker BA Davies FE The genetic architecture of multiple myeloma Nat Rev Cancer 2012 12 5 335 348 22495321 10.1038/nrc3257
3 Anderson KC Carrasco RD Pathogenesis of myeloma Annual review of pathology 2011 6 249 274 10.1146/annurev-pathol-011110-130249 21261519
4 Fonseca R Bergsagel PL Drach J Shaughnessy J Gutierrez N Stewart AK Morgan G Van Ness B Chesi M Minvielle S Neri A Barlogie B Kuehl WM Liebisch P Davies F Chen-Kiang S International Myeloma Working Group molecular classification of multiple myeloma: spotlight review Leukemia 2009 23 12 2210 2221 19798094 10.1038/leu.2009.174 PMC2964268
5 Rossi M Di Martino MT Morelli E Leotta M Rizzo A Grimaldi A Misso G Tassone P Caraglia M Molecular targets for the treatment of multiple myeloma Curr Cancer Drug Targets 2012 12 7 757 767 22671925 10.2174/156800912802429300
6 Morabito F Recchia AG Mazzone C Gentile M Targeted therapy of multiple myeloma: the changing paradigm at the beginning of the new millennium Curr Cancer Drug Targets 2012 12 7 743 756 22671929 10.2174/156800912802429373
7 Demchenko YN Kuehl WM A critical role for the NFkB pathway in multiple myeloma Oncotarget 2010 1 1 59 68 20890394 10.18632/oncotarget.109 PMC2947827
8 Galm O Wilop S Reichelt J Jost E Gehbauer G Herman JG Osieka R DNA methylation changes in multiple myeloma Leukemia 2004 18 10 1687 1692 15318245 10.1038/sj.leu.2403434
9 Galm O Herman JG Baylin SB The fundamental role of epigenetics in hematopoietic malignancies Blood Rev 2006 20 1 1 13 16426940 10.1016/j.blre.2005.01.006
10 Antequera F Structure, function and evolution of CpG island promoters Cell Mol Life Sci 2003 60 8 1647 1658 14504655 10.1007/s00018-003-3088-6 PMC11138798
11 Jones PA Baylin SB The fundamental role of epigenetic events in cancer Nat Rev Genet 2002 3 6 415 428 12042769 10.1038/nrg816
12 Robertson KD DNA methylation, methyltransferases, and cancer Oncogene 2001 20 24 3139 3155 11420731 10.1038/sj.onc.1204341
13 Bestor TH The DNA methyltransferases of mammals Hum Mol Genet 2000 9 16 2395 2402 11005794 10.1093/hmg/9.16.2395
14 Robertson KD Uzvolgyi E Liang G Talmadge C Sumegi J Gonzales FA Jones PA The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors Nucleic Acids Res 1999 27 11 2291 2298 10325416 10.1093/nar/27.11.2291 PMC148793
15 Bakin AV Curran T Role of DNA 5-methylcytosine transferase in cell transformation by fos Science 1999 283 5400 387 390 9888853 10.1126/science.283.5400.387
16 Slack A Cervoni N Pinard M Szyf M DNA methyltransferase is a downstream effector of cellular transformation triggered by simian virus 40 large T antigen J Biol Chem 1999 274 15 10105 10112 10187792 10.1074/jbc.274.15.10105
17 Robertson KD Keyomarsi K Gonzales FA Velicescu M Jones PA Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells Nucleic Acids Res 2000 28 10 2108 2113 10773079 10.1093/nar/28.10.2108 PMC105379
18 LaRochelle O Bertoli S Vergez F Sarry JE Mansat-De Mas V Dobbelstein S Dastugue N Strzelecki AC Cavelier C Creancier L Pillon A Kruczynski A Demur C Sarry A Huguet F Huynh A Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience Oncotarget 2011 2 11 850 861 22081665 10.18632/oncotarget.347 PMC3260002
19 Agoston AT Argani P Yegnasubramanian S De Marzo AM Ansari-Lari MA Hicks JL Davidson NE Nelson WG Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer J Biol Chem 2005 280 18 18302 18310 15755728 10.1074/jbc.M501675200
20 McCabe MT Davis JN Day ML Regulation of DNA methyltransferase 1 by the pRb/E2F1 pathway Cancer Res 2005 65 9 3624 3632 15867357 10.1158/0008-5472.CAN-04-2158
21 Toyota M Kopecky KJ Toyota MO Jair KW Willman CL Issa JP Methylation profiling in acute myeloid leukemia Blood 2001 97 9 2823 2829 11313277 10.1182/blood.v97.9.2823
22 Baylin SB Herman JG DNA hypermethylation in tumorigenesis: epigenetics joins genetics Trends Genet 2000 16 4 168 174 10729832 10.1016/s0168-9525(99)01971-x
23 Saito Y Liang G Egger G Friedman JM Chuang JC Coetzee GA Jones PA Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells Cancer Cell 2006 9 6 435 443 16766263 10.1016/j.ccr.2006.04.020
24 Fabbri M Garzon R Cimmino A Liu Z Zanesi N Callegari E Liu S Alder H Costinean S Fernandez-Cymering C Volinia S Guler G Morrison CD Chan KK Marcucci G Calin GA MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B Proc Natl Acad Sci U S A 2007 104 40 15805 15810 17890317 10.1073/pnas.0707628104 PMC2000384
25 Bartel DP MicroRNAs: genomics, biogenesis, mechanism, and function Cell 2004 116 2 281 297 14744438 10.1016/s0092-8674(04)00045-5
26 Tagliaferri P Rossi M Di Martino MT Amodio N Leone E Gulla A Neri A Tassone P Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma Curr Cancer Drug Targets 2012 12 7 838 846 22671926 10.2174/156800912802429355 PMC3504921
27 Di Martino MT Leone E Amodio N Foresta U Lionetti M Pitari MR Gallo Cantafio ME Gulla A Conforti F Morelli E Tomaino V Rossi M Negrini M Ferrarini M Caraglia M Shammas MA Synthetic miR-34a mimics as a novel therapeutic agent for Multiple Myeloma: in vitro and in vivo evidence Clin Cancer Res 2012 10.1158/1078-0432.CCR-12-1708 PMC4453928 23035210
28 Trang P Wiggins JF Daige CL Cho C Omotola M Brown D Weidhaas JB Bader AG Slack FJ Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice Mol Ther 2011 19 6 1116 1122 21427705 10.1038/mt.2011.48 PMC3129804
29 Calimeri T Battista E Conforti F Neri P Di Martino MT Rossi M Foresta U Piro E Ferrara F Amorosi A Bahlis N Anderson KC Munshi N Tagliaferri P Causa F Tassone P A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells Leukemia 2011 25 4 707 711 21233838 10.1038/leu.2010.300 PMC3089835
30 Tassone P Neri P Burger R Di Martino MT Leone E Amodio N Caraglia M Tagliaferri P Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma Curr Cancer Drug Targets 2012 12 7 814 822 22671927 10.2174/156800912802429292 PMC3587184
31 Krek A Grun D Poy MN Wolf R Rosenberg L Epstein EJ MacMenamin P da Piedade I Gunsalus KC Stoffel M Rajewsky N Combinatorial microRNA target predictions Nat Genet 2005 37 5 495 500 15806104 10.1038/ng1536
32 Lewis BP Shih IH Jones-Rhoades MW Bartel DP Burge CB Prediction of mammalian microRNA targets Cell 2003 115 7 787 798 14697198 10.1016/s0092-8674(03)01018-3
33 Bellizzi D D'Aquila P Montesanto A Corsonello A Mari V Mazzei B Lattanzio F Passarino G Global DNA methylation in old subjects is correlated with frailty Age (Dordr) 34 1 169 179 21336567 10.1007/s11357-011-9216-6 PMC3260357
34 Kanai Y Hirohashi S Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state Carcinogenesis 2007 28 12 2434 2442 17893234 10.1093/carcin/bgm206
35 Mizuno S Chijiwa T Okamura T Akashi K Fukumaki Y Niho Y Sasaki H Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia Blood 2001 97 5 1172 1179 11222358 10.1182/blood.v97.5.1172
36 De Marzo AM Marchi VL Yang ES Veeraswamy R Lin X Nelson WG Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis Cancer Res 1999 59 16 3855 3860 10463569
37 Qu Y Mu G Wu Y Dai X Zhou F Xu X Wang Y Wei F Overexpression of DNA methyltransferases 1, 3a, and 3b significantly correlates with retinoblastoma tumorigenesis Am J Clin Pathol 2010 134 5 826 834 20959668 10.1309/AJCPHGQ69FXDFWII
38 Garzon R Liu S Fabbri M Liu Z Heaphy CE Callegari E Schwind S Pang J Yu J Muthusamy N Havelange V Volinia S Blum W Rush LJ Perrotti D Andreeff M MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1 Blood 2009 113 25 6411 6418 19211935 10.1182/blood-2008-07-170589 PMC2710934
39 Galm O Yoshikawa H Esteller M Osieka R Herman JG SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma Blood 2003 101 7 2784 2788 12456503 10.1182/blood-2002-06-1735
40 Mateos MV Garcia-Sanz R Lopez-Perez R Moro MJ Ocio E Hernandez J Megido M Caballero MD Fernandez-Calvo J Barez A Almeida J Orfao A Gonzalez M San Miguel JF Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival Br J Haematol 2002 118 4 1034 1040 12199782 10.1046/j.1365-2141.2002.03749.x
41 Hodge DR Peng B Cherry JC Hurt EM Fox SD Kelley JA Munroe DJ Farrar WL Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation Cancer Res 2005 65 11 4673 4682 15930285 10.1158/0008-5472.CAN-04-3589
42 Ng MH Chung YF Lo KW Wickham NW Lee JC Huang DP Frequent hypermethylation of p16 and p15 genes in multiple myeloma Blood 1997 89 7 2500 2506 9116295
43 Hatzimichael E Dranitsaris G Dasoula A Benetatos L Stebbing J Crook T Bourantas KL Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease Clin Lymphoma Myeloma 2009 9 3 239 242 19525194 10.3816/CLM.2009.n.047
44 Sengupta S den Boon JA Chen IH Newton MA Stanhope SA Cheng YJ Chen CJ Hildesheim A Sugden B Ahlquist P MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins Proc Natl Acad Sci U S A 2008 105 15 5874 5878 18390668 10.1073/pnas.0801130105 PMC2311339
45 Garzon R Heaphy CE Havelange V Fabbri M Volinia S Tsao T Zanesi N Kornblau SM Marcucci G Calin GA Andreeff M Croce CM MicroRNA 29b functions in acute myeloid leukemia Blood 2009 114 26 5331 5341 19850741 10.1182/blood-2009-03-211938 PMC2796138
46 Pekarsky Y Croce CM Is miR-29 an oncogene or tumor suppressor in CLL? Oncotarget 2010 1 3 224 227 20936047 10.18632/oncotarget.129 PMC2951328
47 Kiziltepe T Hideshima T Catley L Raje N Yasui H Shiraishi N Okawa Y Ikeda H Vallet S Pozzi S Ishitsuka K Ocio EM Chauhan D Anderson KC 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells Mol Cancer Ther 2007 6 6 1718 1727 17575103 10.1158/1535-7163.MCT-07-0010
48 Fulciniti M Hideshima T Vermot-Desroches C Pozzi S Nanjappa P Shen Z Patel N Smith ES Wang W Prabhala R Tai YT Tassone P Anderson KC Munshi NC A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma Clin Cancer Res 2009 15 23 7144 7152 19934301 10.1158/1078-0432.CCR-09-1483 PMC2787636
49 Burger R Guenther A Bakker F Schmalzing M Bernand S Baum W Duerr B Hocke GM Steininger H Gebhart E Gramatzki M Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma The hematology journal : the official journal of the European Haematology Association / EHA 2001 2 1 42 53 11920233 10.1038/sj.thj.6200075
50 Blotta S Jakubikova J Calimeri T Roccaro AM Amodio N Azab AK Foresta U Mitsiades CS Rossi M Todoerti K Molica S Morabito F Neri A Tagliaferri P Tassone P Anderson KC Canonical and non canonical Hedgehog pathway in the pathogenesis of multiple myeloma Blood 2012 10.1182/blood-2011-07-368142 PMC3525024 22821765
51 Amodio N Scrima M Palaia L Salman AN Quintiero A Franco R Botti G Pirozzi P Rocco G De Rosa N Viglietto G Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas Am J Pathol 2010 177 5 2622 2634 20889565 10.2353/ajpath.2010.091075 PMC2966817
52 Livak KJ Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods 2001 25 4 402 408 11846609 10.1006/meth.2001.1262
53 Neri P Tagliaferri P Di Martino MT Calimeri T Amodio N Bulotta A Ventura M Eramo PO Viscomi C Arbitrio M Rossi M Caraglia M Munshi NC Anderson KC Tassone P In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor Br J Haematol 2008 143 4 520 531 18986388 10.1111/j.1365-2141.2008.07387.x
54 Tassone P Di Martino MT Ventura M Pietragalla A Cucinotto I Calimeri T Bulotta A Neri P Caraglia M Tagliaferri P Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo Cancer biology & therapy 2009 8 7 648 653 19333003 10.4161/cbt.8.7.7968
55 Neri P Yasui H Hideshima T Tassone P Raje N Catley LP Ishitsuka K Blotta S Kiziltepe T Ocio EM Fulciniti M Kanekal S Elliott GT Munshi NC Anderson KC In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells Br J Haematol 2006 134 1 37 44 16803565 10.1111/j.1365-2141.2006.06122.x